Regeneron Pharmaceuticals, Inc.

DB:RGO Stock Report

Market Cap: €75.7b

Regeneron Pharmaceuticals Valuation

Is RGO undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

6/6

Valuation Score 6/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of RGO when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: RGO (€701.8) is trading below our estimate of fair value (€2178.73)

Significantly Below Fair Value: RGO is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for RGO?

Key metric: As RGO is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for RGO. This is calculated by dividing RGO's market cap by their current earnings.
What is RGO's PE Ratio?
PE Ratio17.2x
EarningsUS$4.65b
Market CapUS$80.11b

Price to Earnings Ratio vs Peers

How does RGO's PE Ratio compare to its peers?

The above table shows the PE ratio for RGO vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average62.2x
BIO3 Biotest
26.5x82.7%€1.4b
MRK Merck KGaA
22.5x10.7%€60.7b
FYB Formycon
12.8x31.5%€820.2m
SRT3 Sartorius
186.9x36.4%€13.1b
RGO Regeneron Pharmaceuticals
17.2x7.6%€80.1b

Price-To-Earnings vs Peers: RGO is good value based on its Price-To-Earnings Ratio (17.2x) compared to the peer average (62.2x).

Price to Earnings Ratio vs Industry

How does RGO's PE Ratio compare vs other companies in the European Biotechs Industry?

5 CompaniesPrice / EarningsEstimated GrowthMarket Cap
RGO 17.2xIndustry Avg. 27.3xNo. of Companies5PE020406080100+
5 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: RGO is good value based on its Price-To-Earnings Ratio (17.2x) compared to the European Biotechs industry average (27.3x).

Price to Earnings Ratio vs Fair Ratio

What is RGO's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

RGO PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio17.2x
Fair PE Ratio21.7x

Price-To-Earnings vs Fair Ratio: RGO is good value based on its Price-To-Earnings Ratio (17.2x) compared to the estimated Fair Price-To-Earnings Ratio (21.7x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst RGO forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current€701.80
€1,017.95
+45.0%
12.6%€1,161.37€755.36n/a26
Nov ’25€782.20
€1,010.87
+29.2%
11.1%€1,135.04€738.24n/a25
Oct ’25€947.40
€1,036.81
+9.4%
11.7%€1,164.28€734.39n/a25
Sep ’25€1,068.50
€1,038.46
-2.8%
12.0%€1,170.52€724.82n/a25
Aug ’25€1,015.00
€1,036.99
+2.2%
12.9%€1,204.71€667.22n/a25
Jul ’25€975.20
€984.36
+0.9%
12.1%€1,145.18€670.90n/a25
Jun ’25€898.40
€965.10
+7.4%
11.7%€1,091.62€663.26n/a25
May ’25€828.40
€967.70
+16.8%
11.2%€1,108.39€671.18n/a25
Apr ’25€891.50
€940.83
+5.5%
11.3%€1,089.75€653.48n/a25
Mar ’25€890.50
€931.15
+4.6%
11.8%€1,091.65€654.62n/a23
Feb ’25€872.00
€894.07
+2.5%
11.8%€1,038.71€655.54n/a24
Jan ’25€792.50
€828.25
+4.5%
11.6%€1,013.06€630.35n/a24
Dec ’24€759.50
€829.16
+9.2%
10.7%€972.83€620.57n/a25
Nov ’24€748.50
€854.36
+14.1%
10.6%€1,007.40€643.82€782.2023
Oct ’24€786.00
€850.24
+8.2%
10.5%€993.20€643.21€947.4023
Sep ’24€765.50
€821.99
+7.4%
10.8%€963.69€610.34€1,068.5023
Aug ’24€672.50
€776.12
+15.4%
10.6%€945.52€588.12€1,015.0023
Jul ’24€650.00
€790.56
+21.6%
11.7%€957.43€595.53€975.2023
Jun ’24€687.00
€824.66
+20.0%
10.9%€979.76€606.52€898.4023
May ’24€727.00
€796.28
+9.5%
10.5%€942.55€589.10€828.4023
Apr ’24€742.00
€803.74
+8.3%
10.9%€958.78€599.24€891.5023
Mar ’24€715.60
€776.86
+8.6%
12.2%€945.39€565.74€890.5023
Feb ’24€693.20
€743.77
+7.3%
12.5%€943.10€557.75€872.0023
Jan ’24€669.00
€755.70
+13.0%
13.0%€968.87€561.32€792.5023
Dec ’23€727.40
€756.03
+3.9%
13.3%€975.65€546.25€759.5023
Nov ’23€769.60
€790.31
+2.7%
13.4%€1,037.51€582.02€748.5023

Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.

Discover undervalued companies

Perrigo

US$3.7b

Provides over-the-counter health and wellness solutions to enhance individual well-being in the United States, Europe, and internationally.

PIG

US$25.40

7D

1.7%

1Y

-8.9%

Almirall

€1.8b

A biopharmaceutical company, engages in the purchase, manufacture, storage, and sale of skin-health medicines in Europe, the Middle East, the United States, Asia, and Africa.

E2Z

€8.38

7D

-0.5%

1Y

-0.4%

Pharming Group

€481.3m

A biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally.

PHGN

€0.71

7D

-3.5%

1Y

-34.8%